HOME >> MEDICINE >> NEWS
Worsening anemia signals poorer outcomes in men treated for advanced prostate cancer

PORTLAND, Ore. -- Researchers from the Oregon Health & Science University Cancer Institute and Southwest Oncology Group have identified a new method of determining how men with advanced prostate cancer will respond to treatment. They found that worsening anemia during the first three months of hormonal therapy for prostate cancer that has spread predicts shorter survival and earlier relapse.

"These results suggest that by monitoring anemia during the first three months of treatment, we can provide men with a better idea of how well they will fare," said principal investigator Tomasz Beer, M.D., director of the prostate cancer research program in the OHSU Cancer Institute. Beer will present results of this study at the 101st Annual Meeting of the American Urological Association in Atlanta on Tues., May 23.

Researchers also found that race alone was not a strong predictor of survival or disease progression. However, they found that men with the same hemoglobin levels before treatment experienced significantly different overall and progression-free survival depending on whether they were black or white. Hemoglobin levels in the blood are measured to monitor anemia. Lower levels of hemoglobin are considered anemic.

"Outcomes for prostate cancer have always been worse for black men than their white counterparts and the reasons behind this have not been fully understood," Beer said. "Differences in anemia could help us understand why blacks do worse and maybe make it possible to do something about it."

Overall, researchers found that anemic blacks fare worse than anemic whites and that blacks with high baseline hemoglobin fare better than whites with similar hemoglobin levels.

"Our study was not designed to answer questions about this complex and novel finding, but we are examining a number of hypotheses," Beer said.

Anemia is common among newly diagnosed prostate cancer patients with metastatic disease
'"/>

Contact: Rachel MacKnight
macknigh@ohsu.edu
503-494-8231
Oregon Health & Science University
23-May-2006


Page: 1 2 3

Related medicine news :

1. Researchers urge caution in using ESAs for cancer-related anemia
2. Mortality rate increases for kidney recipients with anemia
3. Exercise helps breast cancer patients avoid anemia
4. How bad is malaria anemia? It may depend on your genes
5. Immune culprit in malaria-associated anemia
6. New drug poised to radically change the treatment of severe anemias
7. Hepatitis C drug proves cost-effective in helping patients with treatment-induced anemia
8. Oral liquid hydroxyurea promising for long-term use in babies with sickle cell anemia
9. Study examines effectiveness of anti-anemia drug in treatment of cancer patients
10. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
11. Targeted cancer drugs may work by disrupting balance of cellular signals

Post Your Comments:
(Date:1/22/2015)... 2015 Liberty University has received accreditation for ... from the Council for Accreditation of Counseling & Related ... Center for Counseling & Family Studies , is under ... university’s new School of Behavioral Sciences. Prior to the formation ...
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Cached News: